Cargando…

PB2006: MOLECULAR CLINICAL CHARACTERISTICS AND PROGNOSIS OF MDS PATIENTS WITH RUNX1 MUTATION

Detalles Bibliográficos
Autores principales:	Huang, Nanfang, Song, Yang, He, Qi, Wu, Lingyun, Guo, Juan, Zhang, Zheng, LI, Xiao, Chang, Chunkang, Xu, Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430016/ http://dx.doi.org/10.1097/01.HS9.0000974840.45247.32

Ejemplares similares

PB1801: MYCN IS REQUIRED FOR MAINTAINING AN ONCOGENIC CHARACTERISTICS OF LEUKEMIA CELLS IN ACUTE MYELOID LEUKEMIA
por: Huang, Nanfang, et al.
Publicado: (2023)

PB2013: THE FREQUENCY, EVOLUTION AND SIGNIFICANCE OF GENE MUTATION IN MYELODYSPLASTIC SYNDROMES WITH NORMAL KARYOTYPE
por: Xu, Feng, et al.
Publicado: (2023)

PB2002: ASSOCIATION OF GENE MUTATIONS AND CLINICAL MANIFESTATIONS AND PROGNOSIS IN THE CLINICAL COHORT WITH 218 MDS PATIENTS
por: Wang, Xue’e, et al.
Publicado: (2023)

PB1999: TOBACCO SMOKING IN MDS PATIENTS – ANALYSIS FROM THE MDS PALG REGISTRY
por: Machowicz, Rafal, et al.
Publicado: (2023)

PB2016: HIGH SERUM FERRITIN LEVELS AT DIAGNOSIS PREDICT WORSE PROGNOSIS IN ADVANCED MDS IN CHILDREN.
por: Liu, Chenmeng, et al.
Publicado: (2023)

PB1793: NEUTROPHIL TO LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR IN AML AND MDS
por: Van Oorschot, V., et al.
Publicado: (2022)

PB2032: FACTORS ASSOCIATED WITH TRANSFUSION INDEPENDENCY POST TREATMENT IN HIGH RISK MDS PATIENTS
por: Fatima, Naveena, et al.
Publicado: (2023)

PB1989: STUDY ON THE RELATIONSHIP BETWEEN MDS AND ABNORMAL LIPID METABOLISM IN BONE MARROW MICROENVIRONMENT
por: LI, Yuchun, et al.
Publicado: (2023)

PB2060: THE MDS-SPECIFIC COMORBIDITY INDEX (MDS-CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION.
por: Koster, K.-L., et al.
Publicado: (2022)

PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY
por: de Botton, Stéphane, et al.
Publicado: (2023)

PB2657: DIFFERENT TYPES OF LEUKEMIAS AND BLEEDING DISORDER DETECTED IN A TURKISH FAMILY WITH GERMLINE RUNX1 MUTATION FOR THE FIRST TIME.
por: Ata, Pinar, et al.
Publicado: (2023)

PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)
por: DeZern, A., et al.
Publicado: (2022)

PB2670: EQOL-MDS TRIAL: PATIENT-REPORTED OUTCOMES IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH SEVERE THROMBOCYTOPENIA.
por: Oliva, Esther, et al.
Publicado: (2023)

PB2023: THE LEVEL OF VASCULAR ENDOTHELIAL FACTOR (VEGF) IN THE BLOOD SERUM OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS RAEB I).
por: Стародуб, Галина, et al.
Publicado: (2023)

PB2006: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH PLASMA CELL LEUKEMIA (PCL): A SINGLE-CENTER STUDY FROM TUNISIA
por: Fakhfakh, Y., et al.
Publicado: (2022)

PB1991: NEW MONOCYTE HEMATOLOGICAL PARAMETERS AS AN IMPORTANT INDICATOR OF MDS PATIENTS WITH POSITIVE OGATA SCORE - A PRELIMINARY STUDY
por: Dudzik, Alicja, et al.
Publicado: (2023)

PB1922: EFFECTIVENESS OF AZACITIDINE IN FRONTLINE HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS): A RETROSPECTIVE COHORT STUDY OF 382 PATIENTS
por: Rajakumaraswamy, N., et al.
Publicado: (2022)

PB1800: CLINICAL CHARACTERISTICS AND MUTATION LANDSCAPE OF TRISOMY AML
por: Lam, Stephen S Y, et al.
Publicado: (2023)

PB2367: CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH NODAL PERIPHERAL T-CELL LYMPHOMA
por: Yahia, Noura Ben, et al.
Publicado: (2023)

PB1925: VENETOCLAX IN COMBINATION WITH AZACITIDINE OR LOW-DOSE CYTARABINE IN PATIENTS WITH HIGH-RISK MDS AND AML - EXPERIENCE OF A CZECH HAEMATOLOGY CENTRE.
por: Minarik, L., et al.
Publicado: (2022)

PB1919: S100A9 DEFICIENCY ACCELERATES MDS ASSOCIATED TUMOR ESCAPE VIA PD-1/PD-L1 OVEREXPRESSION
por: Wang, R., et al.
Publicado: (2022)

PB1860: CLONALITY RELATEDNESS AND MOLECULAR CHARACTERISTICS OF RICHTER SYNDROME
por: Sha, Y., et al.
Publicado: (2022)

PB1770: CHARACTERIZATION OF THE MUTATIONAL PROFILE OF PATIENTS WITH CBF-AML - HETEROGENEITY AND IMPACT ON THE PROGNOSIS
por: Motyko, Ekaterina, et al.
Publicado: (2023)

PB1894: NPM1 MUTATED ACUTE MYELOID LEUKEMIA: THE CO-MUTATION PATTERNS MAY BE ASSOCIATED WITH PROGNOSIS
por: Varelas, Christos, et al.
Publicado: (2023)

PB1765: DIFFERENTIAL GENE EXPRESSION PROFILE IN DNA DAMAGE SIGNALING PATHWAYS, IN DE NOVO ACUTE MYELOID LEUKEMIA AND LOW-RISK MDS PATIENTS
por: Bouchla, Anthi, et al.
Publicado: (2023)

PB1816: RUNX1 GERMLINE VARIANT AND CLONAL EVOLUTION TO ACUTE MYELOID LEUKEMIA – A FPDMM FAMILY STUDY
por: Amorim, Maria Luís, et al.
Publicado: (2023)

PB1926: REAL-WORLD ERYTHROPOIESIS-STIMULATING AGENT (ESA) TREATMENT PATTERNS AND OUTCOMES AMONG US PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS)
por: Mukherjee, S., et al.
Publicado: (2022)

PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
por: Zeidan, Amer M., et al.
Publicado: (2023)

PB2003: REAL-WORLD TREATMENT PATTERNS OF PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) IN A US REAL-WORLD EVIDENCE DATABASE (COTA)
por: Komrokji, Rami S., et al.
Publicado: (2023)

PB1946: NOTCH PATHWAY MUTATION CONTRIBUTES TO INFERIOR PROGNOSIS IN HBV-INFECTED CHRONIC LYMPHOCYTIC LEUKEMIA
por: Shang, Chunyu, et al.
Publicado: (2023)

PB1965: INSIGHTS INTO RELAPSED AND REFRACTORY CHRONIC MYELOID LEUKEMIA: MOLECULAR-GENETIC, BIOCHEMICAL AND PROGNOSIS PATTERNS
por: Musteata, Vasile
Publicado: (2023)

PB2193: JAK2 V617F MUTATION BURDEN DETECTION AND RELATIONSHIP WITH LABORATORY CHARACTERISTICS IN MYELOPROLIFERATIVE NEOPLASMS
por: MA, Xuefei, et al.
Publicado: (2023)

PB2542: MOLECULAR SPECTRUM OF ALPHA THALASSEMIA MUTATIONS IN THE WESTERN PROVINCE OF SAUDI ARABIA AND RECOMMENDATION FOR PREMARITAL SCREENING
por: Attallah, Samy, et al.
Publicado: (2023)

PB2190: COMORBIDITIES PREDICT WORSE PROGNOSIS IN PATIENTS WITH POLYCYTHEMIA VERA
por: Arsenović, Isidora, et al.
Publicado: (2023)

PB1858: PROGNOSIS AND TREATMENT OF FLT3 MUTATED MYELOID SARCOMA IN THE ERA OF FLT3 INHIBITORS: RETROSPECTIVE EVALUATION IN 5 ITALIAN CENTERS.
por: Lessi, Federica, et al.
Publicado: (2023)

PB1945: CLINICAL AND MOLECULAR CHARACTERISTICS OF CHILDREN WITH DIAMOND-BLACKFAN ANEMIA (DBA): A SINGLE CENTER EXPERIENCE IN ARGENTINA
por: Mininni, M. F., et al.
Publicado: (2022)

PB2223: CLINICOPATHOLOGICAL, CYTOGENETIC AND MOLECULAR CHARACTERISTICS OF PATIENTS WITH NON-CML MYELOPROLIFERATIVE NEOPLASMS: A SINGLE CENTER STUDY
por: Guntiboina, Vinay Anand, et al.
Publicado: (2023)

PB2124: MYC EXPRESSION ANALYSIS AND PROGNOSIS VALUE IN TRANSFORMED FOLLICULAR LYMPHOMA
por: Liang, J., et al.
Publicado: (2022)

PB2539: GEOGRAPHICAL PREVALENCE OF THALASSEMIA GENE MUTATION IN THE PHILIPPINES
por: Velasco, Manuel Jr, et al.
Publicado: (2023)

PB2391: FREQUENCY OF IKZF3 MUTATION IN WALDENSTRÖM’S MACROGLOBULINEMIA
por: Taleb, Assia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l0f187pa37629beah0budu53p6